Glenmark Pharmaceuticals Ltd.’s rhinitis therapy Ryaltris (olopatadine HCl/mometasone furoate) has been approved in Australia, the first market where the fixed‐dose combination nasal spray is expected to be launched next year.
Glenmark said that its partner Seqirus Pty. Ltd. had received marketing clearance for Ryaltris from the Therapeutic Goods Administration (TGA),...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)


